Overview

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disorder.

Phase:

PHASE3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Lamotrigine
Lithium
trospium chloride
Valproic Acid
xanomeline